June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Clinical outcomes, short-term survival and complications of Lucia Keratoprosthesis
Author Affiliations & Notes
  • Carlos Adolfo Muller Morales
    Córnea, Instituto de Oftalmologia Fundacion Conde de Valenciana IAP, Mexico City, Mexico City, Mexico
  • Karla Maria Arteaga-Rivera
    Córnea, Instituto de Oftalmologia Fundacion Conde de Valenciana IAP, Mexico City, Mexico City, Mexico
  • David Jimenez-Collado
    Córnea, Instituto de Oftalmologia Fundacion Conde de Valenciana IAP, Mexico City, Mexico City, Mexico
  • Arturo Ramírez-Miranda
    Córnea, Instituto de Oftalmologia Fundacion Conde de Valenciana IAP, Mexico City, Mexico City, Mexico
  • Alejandro Navas
    Córnea, Instituto de Oftalmologia Fundacion Conde de Valenciana IAP, Mexico City, Mexico City, Mexico
  • Enrique O Graue-Hernandez
    Córnea, Instituto de Oftalmologia Fundacion Conde de Valenciana IAP, Mexico City, Mexico City, Mexico
  • Footnotes
    Commercial Relationships   Carlos Muller Morales None; Karla Arteaga-Rivera None; David Jimenez-Collado None; Arturo Ramírez-Miranda None; Alejandro Navas None; Enrique Graue-Hernandez None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 4353 – A0290. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Carlos Adolfo Muller Morales, Karla Maria Arteaga-Rivera, David Jimenez-Collado, Arturo Ramírez-Miranda, Alejandro Navas, Enrique O Graue-Hernandez; Clinical outcomes, short-term survival and complications of Lucia Keratoprosthesis. Invest. Ophthalmol. Vis. Sci. 2022;63(7):4353 – A0290.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report visual outcomes, survival rate and short-term complications in patients treated with Lucia KPRO.

Methods : All eligible patients were included. Suitable patients for keratoprosthsis surgery were those who weren't candidates for conventional PKP, including severe bilateral limbal stem cell disease, history of repeat corneal graft failure, ocular surface chemical burns or immune mediated ocular surface disease. Analyzed variables include diagnosis prior to transplantation, age, gender, BCVA, IOP, and postop complications. Descriptive analysis was performed using Excel (Microsoft, Redmond, WA) and statistical analysis was performed using StatPlus (StatPlus, Version 6, AnalystSoft Inc., Walnut, CA). Chisquare test was used to analyze categorical data. Normality test was performed to determine if a data is normally distributed.Preop and postop LogMAR VA were determined to be normally distributed. Then, paired two-tailed t-test was used to compare VA. Statistical significance was set at p < 0.05. Log-rank test was performed on Kaplan-Meier survival curves for maintenance of VA and device retention.

Results : 20 eyes of 19 patients were included . Mean age 53.85±17.25 yo. Average follow up 95.3±69.89 days. Previous transplants were performed in 13 eyes (65%), in 7 eyes (35%) KPRO implant was the primary procedure. Mean preop VA 2.40±0.38 logMAR, immediate postop VA was 1.08±0.67 logMAR and 0.98±0.99 logMAR at end of follow up (6 mo) having a statistically significant improvement (p<0.05). Most frequent complication was ocular hypertension in the immediate postoperative 25%, retroprothesic membrane formation 5%, sterile vitretiis 10% and corneal thinning around the optic 10%. 11 eyes (55%) had prior diagnosis of glaucoma and 1 eye had corneal dehiscence secondary to trauma. 5 patients required a second surgical intervention to address complications: 2 amniotic membrane grafts, 1 vitrectomy and cyclodestructive procedure for uncontrolled IOP, 1 antibiotic/steroid intravitreal inyections for sterile vitreiitis, and 1 KPRO re-suturing for dehiscence. Device retention throughout the follow-up period was 100%.

Conclusions : First short-term study reporting Lucia KPRO outcomes. All patients improved VA and 100% retention rate. Results are comparable with type I Boston KPRO with the undoubtable advantage of reaching a higher quantity of patients because of its costs, especially in our population.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×